Format

Send to

Choose Destination
J Neuroimmunol. 2011 Apr;233(1-2):221-7. doi: 10.1016/j.jneuroim.2010.12.001. Epub 2011 Jan 15.

Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression.

Author information

1
P. K. Anokhin Institute of Normal Physiology RAMS, Mohovaya St. 11, Building 4, 125009 Moscow, Russia.

Erratum in

  • J Neuroimmunol. 2014 Mar 15;268(1-2):99. Bocharova, Olga R [corrected to Bocharova, Olga A].

Abstract

The aim was to ascertain any possible linkage between humoral immune responses to principal biomarkers (α-synuclein monomers, its toxic oligomers or fibrils, dopamine and S100B) and cellular immunity in Parkinson's disease development. There were elevated autoantibody titers to α-synuclein monomers, oligomers plus fibrils in 72%, 56%, and 17% of Parkinsonian patients respectively with a 5-year disease duration. Additionally, there were increased titers to dopamine and S100B (96% and 89%) in the 5-year patient group. All of these values subsided in 10-year sufferers. Furthermore, CD3+, CD4+, CD8+ T-lymphocyte and B-lymphocyte subsets declined in the patient cohort during Parkinsonism indicating disease associated reductions in these lymphocyte subsets.

PMID:
21239064
DOI:
10.1016/j.jneuroim.2010.12.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center